诺瓦瓦克斯医药于5月16日获得了美国食品和药物管理局(FDA)对其COVID-19生物-疫苗Nuvaxovid的批准,依据同日文件。
该生物疫苗已批准用于65岁及以上人群,以及12岁至64岁且有基础医疗控件的人群。
FDA还要求该生物技术公司在未来几年内进行Nuvaxovid的效益及其与心脏病相关的额外试验。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.